mpre, I appreciate the value and share your excitement of being invested in science that could potentially save lives and help otherwise hopeless patients. I also believe that ADXS' products, at least some of them, will make it to market, most probably as part of a big pharma's portfolio. My commentary is simply on the increasingly depressing situation that small cap biotechs find themselves in, thanks to crooks who control the market.
Imagine if ADXS had just ONE undisputed science failure; management then would have had to deal with the market equivalent of payday lenders to finance themselves before dying a slow and agonizing death. This should never be the case for biotechs that have multiple products with potential in their pipelines. Hedge funds have eliminated the margin for error for clinical biotechs that intend to use the markets to raise money on reasonable terms. Also, from the standpoint of retail investors, let's not forget that it took the collective effort of a whole bunch of us long term longs to figure out the multi year hedge fund scheme that was perpetrated here.
Sure, there are lessons that many of us have learned but if the primary lesson for retail is to hedge our bets just like the funds do, without their HFT machines and their machinations, and having to second guess their illegal schemes, then I would say many will simply exit this sector. My second biggest regret is that ADXS couldn't stick it to these low life funds, the first, of course, being my own failure to hedge better. I am lucky to have had some multi baggers in the tech and oil sectors to cushion my paper losses here and keep me standing. However, once ADXS is hopefully bought out, I have to get off the biotech train to keep my sanity and to de-stress.
News 
Market Data 
Discover 
